<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03605927</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-19305</org_study_id>
    <nct_id>NCT03605927</nct_id>
  </id_info>
  <brief_title>CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease</brief_title>
  <official_title>CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety and efficacy of the addition of BMS-986004
      to standard of care Sirolimus (SIR)-based immune suppression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The approach builds upon extensive evidence supporting the benefit of CD40L blockade in
      disrupting key signaling events associated with immune activation. The trial addresses a
      pressing clinical need, namely prevention of Graft-Versus-Host Disease (GVHD) after
      hematopoietic cell transplantation (HCT) and promotion of donor-recipient immune tolerance.
      The safety profile of this anti-CD40L antibody overcomes major prior limitations, and the
      planned biologic studies will provide significant mechanistic insight.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Grade II-IV Acute Graft-versus Host Disease</measure>
    <time_frame>1 year post HCT</time_frame>
    <description>Cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) by day 100 after hematopoietic cell transplantation (HCT). Acute GVHD severity will be determined by standard Consensus Criteria, and the cumulative incidence of grade II-IV acute GVHD will be reported through day 100 post-HCT, with relapse and death as competing risk events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft-versus Host Disease Through 1 Year Post HCT</measure>
    <time_frame>1 year post HCT</time_frame>
    <description>NIH criteria defined chronic graft-versus-host disease through 1 year post-HCT. Chronic GVHD will be defined by the presence of chronic GVHD defining features, regardless of time post-HCT, in keeping with the NIH Consensus Criteria on diagnosis and staging of chronic GVHD. Individual affected organs are staged on 0-3 severity scale, and summarized for an overall global severity score. The presence of acute GVHD features defines the following subgroups: (1) late acute GVHD (sole presence of acute GVHD features after day 100 post-HCT), (2) overlap subtype of chronic GVHD (co-occurrence of chronic and acute GVHD features, and (3) classic chronic GVHD (absence of concurrent acute GVHD features).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malignancy Relapse Post-HCT</measure>
    <time_frame>1 year post HCT</time_frame>
    <description>Defined as hematologic relapse or any unplanned intervention (including withdrawal of immune suppression) to prevent progression of disease in patients with evidence (molecular, cytogenetic, flow cytometric, radiographic) of malignant disease after HCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>1 year post HCT</time_frame>
    <description>Defined as death in the absence of malignancy relapse post-HCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1 year post HCT</time_frame>
    <description>Defined as time from HCT to death or censoring for last follow up.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Glucocorticoid Exposure</measure>
    <time_frame>1 year post HCT</time_frame>
    <description>Systemic steroid (prednisone or equivalent) dose per kg of recipient body weight will be collected at each study visit, and overall exposure determined.</description>
  </other_outcome>
  <other_outcome>
    <measure>Neutrophil and Platelet Engraftment</measure>
    <time_frame>1 year post HCT</time_frame>
    <description>Stable engraftment is defined as a sustained absolute neutrophil count &gt; 500 over 3 days, as well as a sustained platelet count of &gt; 20 over 7 days without transfusion support. Time to engraftment is defined as time from day 0 to day of sustained engraftment per above criteria.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Graft-versus-host-disease</condition>
  <condition>GVHD</condition>
  <condition>GVHD, Acute</condition>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986004: From day 13, intravenously (IV) every 2 week through day 100 post HCT.
Tacrolimus: From day -3 as standard of care. Sirolimus: From day -1 as standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986004</intervention_name>
    <description>BMS-986004 will be administered in ascending dose cohorts in the phase I component of the trial. Based on prior PK and PD data, dose levels of 225 mg, 675 mg, and 1500 mg (3 total phase I dose levels) will be examined. BMS-986004 will be given intravenously (IV) every 2 weeks, starting from day -3 (i.e., three days prior to HCT) onward through a total of 100 days post-HCT. The maximum tolerated dose (MTD) identified in the phase I component of the trial will be carried forward as the recommended phase II dose.</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>Anti-CD40L Domain Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.
Sirolimus (SIR) will be given as a loading dose on day -1 orally, then daily as maintenance therapy with target levels of 10-14ng/mL early post-HCT, then tapered to 5-14ng/mL range.
Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions.</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>Standard of Care</other_name>
    <other_name>SIR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Sirolimus and tacrolimus (standard of care pharmacologic immune suppression) will be given according to institutional standards.
In brief, tacrolimus (TAC) will be started on day -3 IV, and transitioned to oral TAC when oral medications are tolerated; target level is 3-7ng/mL.
Program standards will be used for SIR and TAC level monitoring frequency and dose adjustments, including careful attention to drug-interactions.</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>Standard of Care</other_name>
    <other_name>TAC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematologic malignancy or blood disorder requiring allogeneic HCT

          -  Adequate vital organ function

          -  Karnofsky Performance Status Score (KPS) â‰¥ 80%

          -  Participants must have an available 8/8 HLA-A, -B, -C, and -DRB1 matched-related or
             unrelated donor

        Exclusion Criteria:

          -  Active infection not controlled with appropriate antimicrobial therapy

          -  HIV, hepatitis B or C infection

          -  HCT-CI (comorbidity index) &gt; 4

          -  Anti-thymocyte globulin, or cyclophosphamide administered within 14 days before or
             planned to receive with HCT conditioning or as part of GVHD prophylaxis in the 14 days
             after HCT

          -  Planned Post transplant maintenance therapies such as FLT3 inhibitor, tyrosine kinase
             inhibitor, JAK inhibitors etc. are not allowed in phase 1 part B and Phase 2 portions
             of the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Khimani, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay Chanea</last_name>
      <phone>626-218-2340</phone>
      <email>kchanea@coh.org</email>
    </contact>
    <investigator>
      <last_name>Haris Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Burton</last_name>
      <phone>813-745-1537</phone>
      <email>Michelle.Burton@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Farhad Khimani, M.D.</last_name>
      <phone>813-745-1867</phone>
      <email>farhad.khimani@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Farhad Khimani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Alsina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Davila, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederick Locke, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asmita Mishra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Nieder, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taiga Nishihori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Ochoa-Bayona, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lia Perez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Pidala, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rawan Faramand, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Doris Hansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica MacMurray</last_name>
      <phone>614-685-4356</phone>
      <email>jessica.macmurray@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Hannah Chloe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.moffitt.org/research--clinical-trials/clinical-trials</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCT</keyword>
  <keyword>hematopoietic cell transplantation</keyword>
  <keyword>antibody therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

